Paradigm Biopharmaceuticals (PAR.ASX) have $108M in cash, no debt and are well advanced in the progression of clinical trials in addressable markets worth up to as much as $36B p.a. The next two years are particularly exciting for Paradigm Biopharmaceuticals as they are set to announce: Complete recruitment of 1150 patients for the stage 3-clinical […]
Level 9 365 Little Collins Street Melbourne VIC 3000
ROB HAY
Head of Distribution & Investor Relations
M: 0423 345 975
E: rhay@csvf.com.au
The Collins Street Value Fund (CSVF) is managed by Collins St Asset Management Pty Ltd (CSAM) AFSL 468935. CSAM is authorised to provide financial services to wholesale clients only (as set out in section 761G (7) of the Corporations Act 2001).
Speak with our Equity Market Specialists about how we drive superior investment returns through patience, objectivity and freedom. Available after hours by appointment.
©2023 Collins St Asset Management Pty Ltd – Privacy Policy
Available to Wholesale Investors. Past performance is not a reliable indicator of future performance. AFSL 468935. Our Privacy Policy can be accessed here.
Information from Mercer has been obtained from a range of third party sources. While the information is believed to be reliable, Mercer has not sought to verify it independently. As such, Mercer makes no representations or warranties as to the accuracy of the information presented and takes no responsibility or liability (including for indirect, consequential or incidental damages), for any error, omission or inaccuracy in the data supplied by any third party.
